Table 3.
Side effects in COVID-19 vaccine.
| Vaccine | Platform | SARS-CoV-2 antigens | Side effects | Developer | Reference |
|---|---|---|---|---|---|
| ChAdOx1 nCov-19(AZD-1222)a | ChAd-vectored, non-replicating | Expressing S protein | Thrombotic thrombocytopenic | University of Oxford, AstraZeneca | (123) |
| Ad26.COV2-Sa | Ad26-vectored, non-replicating | Expressing S protein | Thrombotic thrombocytopenic, cerebral venous sinus thrombosis | Johnson & Johnson | (124) |
| BNT162b1a | Lipid nanoparticle–mRNA | RBD of S protein | Anaphylactic reactions, Guillain-Barre Syndrome (GBS) | BioNTech, Pfizer, Fosun Pharma | (125–127) |
| v451 | Protein subunit | Molecular clamp-stabilized S protein | False positive HIV tests | University of Queensland | (128) |
| mRNA-1273a | Lipid nanoparticle–mRNA | Expressing S protein | Anaphylactic reactions | Moderna, NIAID | (129) |
ameans that these vaccines selected for US Operation Warp Speed.